Summary
53 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 29% a year over the last 3 years.
- It could repay all its net debt from 1.3 years of operating profit.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 EUR of revenue, only 2.0 EUR is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.8 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 20% a year. Earnings per share grew by 29% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 EUR of revenue goes
- Cost of sales 66 EUR
- Research and development 11 EUR
- Sales and administration 19 EUR
- Taxes and other 1.3 EUR
- Net profit 3.8 EUR
Net profit, industry median (Medical - Devices) 6.9 EUR
Out of every 100 EUR of revenue, 3.8 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.52%
- Paid out of profit
- 59%
- Raised in a row
- 1 year
You receive $0.29 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.